Prescribed hypocaloric nutrition support for critically-ill adults

Background There are controversies about the amount of calories and the type of nutritional support that should be given to critically‐ill people. Several authors advocate the potential benefits of hypocaloric nutrition support, but the evidence is inconclusive. Objectives To assess the effects of prescribed hypocaloric nutrition support in comparison with standard nutrition support for critically‐ill adults Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Cochrane Library), MEDLINE, Embase and LILACS (from inception to 20 June 2017) with a specific strategy for each database. We also assessed three websites, conference proceedings and reference lists, and contacted leaders in the field and the pharmaceutical industry for undetected/unpublished studies. There was no restriction by date, language or publication status. Selection criteria We included randomized and quasi‐randomized controlled trials comparing hypocaloric nutrition support to normo‐ or hypercaloric nutrition support or no nutrition support (e.g. fasting) in adults hospitalized in intensive care units (ICUs). Data collection and analysis We used standard methodological procedures expected by Cochrane. We meta‐analysed data for comparisons in which clinical heterogeneity was low. We conducted prespecified subgroup and sensitivity analyses, and post hoc analyses, including meta‐regression. Our primary outcomes were: mortality (death occurred during the ICU and hospital stay, or 28‐ to 30‐day all‐cause mortality); length of stay (days stayed in the ICU and in the hospital); and Infectious complications. Secondary outcomes included: length of mechanical ventilation. We assessed the quality of evidence with GRADE. Main results We identified 15 trials, with a total of 3129 ICU participants from university‐associated hospitals in the USA, Colombia, Saudi Arabia, Canada, Greece, Germany and Iran. There are two ongoing studies. Participants suffered from medical and surgical conditions, with a variety of inclusion criteria. Four studies used parenteral nutrition and nine studies used only enteral nutrition; it was unclear whether the remaining two used parenteral nutrition. Most of them could not achieve the proposed caloric targets, resulting in small differences in the administered calories between intervention and control groups. Most studies were funded by the US government or non‐governmental associations, but three studies received funding from industry. Five studies did not specify their funding sources. The included studies suffered from important clinical and statistical heterogeneity. This heterogeneity did not allow us to report pooled estimates of the primary and secondary outcomes, so we have described them narratively. When comparing hypocaloric nutrition support with a control nutrition support, for hospital mortality (9 studies, 1775 participants), the risk ratios ranged from 0.23 to 5.54; for ICU mortality (4 studies, 1291 participants) the risk ratios ranged from 0.81 to 5.54, and for mortality at 30 days (7 studies, 2611 participants) the risk ratios ranged from 0.79 to 3.00. Most of these estimates included the null value. The quality of the evidence was very low due to unclear or high risk of bias, inconsistency and imprecision. Participants who received hypocaloric nutrition support compared to control nutrition support had a range of mean hospital lengths of stay of 15.70 days lower to 10.70 days higher (10 studies, 1677 participants), a range of mean ICU lengths of stay 11.00 days lower to 5.40 days higher (11 studies, 2942 participants) and a range of mean lengths of mechanical ventilation of 13.20 days lower to 8.36 days higher (12 studies, 3000 participants). The quality of the evidence for this outcome was very low due to unclear or high risk of bias in most studies, inconsistency and imprecision. The risk ratios for infectious complications (10 studies, 2804 participants) of each individual study ranged from 0.54 to 2.54. The quality of the evidence for this outcome was very low due to unclear or high risk of bias, inconsistency and imprecision We were not able to explain the causes of the observed heterogeneity using subgroup and sensitivity analyses or meta‐regression. Authors' conclusions The included studies had substantial clinical heterogeneity. We found very low‐quality evidence about the effects of prescribed hypocaloric nutrition support on mortality in hospital, in the ICU and at 30 days, as well as in length of hospital and ICU stay, infectious complications and the length of mechanical ventilation. For these outcomes there is uncertainty about the effects of prescribed hypocaloric nutrition, since the range of estimates includes both appreciable benefits and harms. Given these limitations, results must be interpreted with caution in the clinical field, considering the unclear balance of the risks and harms of this intervention. Future research addressing the clinical heterogeneity of participants and interventions, study limitations and sample size could clarify the effects of this intervention.Fil: Perman, Mario I. Hospital Italiano; ArgentinaFil: Ciapponi, Agustín. Instituto de Efectividad Clínica y Sanitaria; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Franco, Juan V.A.. Hospital Italiano; ArgentinaFil: Loudet, Cecilia. Universidad Nacional de La Plata; ArgentinaFil: Crivelli, Adriana. Hospital HIGA San Martín; ArgentinaFil: Garrote, Virginia. Hospital Italiano; ArgentinaFil: Perman, Gastón. Hospital Italiano; Argentin

Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model

<p>Abstract</p> <p>Background</p> <p>Mounting evidence shows that multi-intervention programmes for hypertension treatment are more effective than an isolated pharmacological strategy. Full economic evaluations of hypertension management programmes are scarce and contain methodological limitations. The aim of the study was to evaluate if a hypertension management programme for elderly patients is cost-effective compared to usual care from the perspective of a third-party payer.</p> <p>Methods</p> <p>We built a cost-effectiveness model using published evidence of effectiveness of a comprehensive hypertension programme vs. usual care for patients 65 years or older at a community hospital in Buenos Aires, Argentina. We explored incremental cost-effectiveness between groups. The model used a life-time framework adopting a third-party payer's perspective. Incremental cost-effectiveness ratio (ICER) was calculated in International Dollars per life-year gained. We performed a probabilistic sensitivity analysis (PSA) to explore variable uncertainty.</p> <p>Results</p> <p>The ICER for the base-case of the "Hypertension Programme" versus the "Usual care" approach was 1,124 International Dollars per life-year gained. PSA did not significantly influence results. The programme had a probability of 43% of being dominant (more effective and less costly) and, overall, 95% chance of being cost-effective.</p> <p>Discussion</p> <p>Results showed that "Hypertension Programme" had high probabilities of being cost-effective under a wide range of scenarios. This is the first sound cost-effectiveness study to assess a comprehensive hypertension programme versus usual care. This study measures hard outcomes and explores robustness through a probabilistic sensitivity analysis.</p> <p>Conclusions</p> <p>The comprehensive hypertension programme had high probabilities of being cost-effective versus usual care. This study supports the idea that similar programmes could be the preferred strategy in countries and within health care systems where hypertension treatment for elderly patients is a standard practice.</p

Beers criteria to identify the consumption of potentially inappropriate medication: Adaptation for its application in Argentina

Introducción. Los Criterios de Beers son los más utilizados para evaluar el uso de medicación potencialmente inapropiada en grandes poblaciones, pero no contemplan algunos medicamentos de uso frecuente fuera de los EE.UU. Objetivo. Realizar una adaptación al contexto de Argentina de los Criterios de Beers publicados en 2019. Métodos. Fue elaborada una lista preliminar de medicación potencialmente inapropiada adaptada a la comercialización local, que luego fue consensuada por un panel de expertos (método Delphi). Resultados. De los 112 medicamentos originales listados en la tabla dos de los Criterios de Beers (en forma individual o como grupo), fueron excluidos 36 por no estar disponibles en Argentinae el país y fueron sumados 23 que no se comercializan en los EE.UU. pero sí en Argentina. Luego de dos rondas y de consensuar la suma a esta lista de dos grupos farmacológicos (antimigrañosos y vasodilatadores periféricos), fue acordado el agregado de picosulfato, bisacodilo, senósidos y cáscara sagrada como medicación potencialmente inapropiada en el grupo de agentes contra el estreñimiento, la fluoxetina entre los inhibidores selectivos de la recaptación de serotonina y el Gingko biloba como droga contra la demencia. También hubo consenso en advertir el riesgo de hipotensión ortostática asociado a la tamsulosina, en aconsejar la consideración de la carga anticolinérgica total del esquema terapéutico administrado y en recomendar al paracetamol como primera línea de tratamiento del dolor, asociado o no a opioides. Conclusiones. Contar con una versión de los Criterios de Beers 2019 adaptada al contexto de Argentina contribuirá al desarrollo y monitoreo de intervenciones para prevenir y reducir el consumo de medicación potencialmente inapropiada.Introduction. The Beers Criteria is the most widely used criteria to assess the use of potentially inappropriate medication in large populations, but they do not include some medications that are frequently used outside the United States. Objective. To make an adaptation of the Beers Criteria published in 2019 to the context of Argentina. Methods. A preliminary list of potentially inappropriate medication adapted to local market and practice was designed, which was then agreed upon by a panel of experts (Delphi method). Results. Of the 112 original drugs in the table 2 of the Beers Criteria (individually or as a group), 36 were excluded because they were not available in Argentina and 23 locally marketed drugs but not in the US were included. After two rounds and agreeing to add two additional pharmacological groups to this list (antimigraine and peripheral vasodilators), it was decided to add picosulfate, bisacodyl, sennosides and cascara sagrada as potentially inappropriate medication in the group of anti-constipation agents, fluoxetine among the selective serotonin reuptake inhibitors and Ginkgo biloba as an antidementia drug. There was also consensus in warning about the risk of orthostatic hypotension associated with tamsulosin, in advising consideration of the total anticholinergic load of the therapeutic regimen administered, and in recommending paracetamol as the first line of pain treatment, associated or not with opioids. Conclusions. Having a version of the Beers Criteria 2019 adapted to the Argentine context will contribute to the development and monitoring of interventions to prevent and reduce the consumption of potentially inappropriate medication.Fil: Calabro, Pablo. Hospital Italiano; ArgentinaFil: Donniani, Ileana. Hospital Italiano; ArgentinaFil: Bellomo, Maria Jose. Hospital Italiano; ArgentinaFil: Mozeluk, Natalia. Hospital Italiano; ArgentinaFil: Elizondo, Cristina María. Hospital Italiano; ArgentinaFil: Perman, Gastón. Hospital Italiano; ArgentinaFil: Schapira, Marcelo. Hospital Italiano; ArgentinaFil: Gibert, Marcela Fabiana. Hospital Italiano; ArgentinaFil: Terrasa, Sergio Adrian. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Hospital Italiano. Instituto Universitario. Escuela de Medicina; Argentin

Evaluación de la oferta de alimentos libres de gluten en locales de comida elaborada en la Ciudad Autónoma de Buenos Aires

La enfermedad celíaca es una enteropatía autoinmune. Su tratamiento consiste en suspender definitivamente el gluten en la dieta, lo cual representa un desafío en el consumo de comidas elaboradas. Objetivo. Describir la oferta segura de alimentos elaborados libres de gluten en 3 barrios de la ciudad de Buenos Aires representativos del nivel económico alto, medio y bajo. Métodos. Estudio de corte transversal. Monitores especialmente entrenados evaluaron la oferta de alimentos libres de gluten en locales de comida elaborada mediante observación directa estandarizada. En casos donde esto fue imposible, se realizó en forma indirecta, a través de una entrevista estructurada al personal de dicho local. Se clasificó la oferta de platos por categorías y se evaluaron especialmente las etapas de almacenamiento, elaboración y distribución de los alimentos. Resultados. Se incluyeron 112 locales. Los resultados, para los barrios representativos del nivel económico alto, medio y bajo, respectivamente, fueron: locales sin ningún plato libre de gluten: 27,5% (45/62); 27,0% (27/37) y 30,8% (9/13), (p = 0,96); almacenamiento adecuado en el 12,9% (8), 13,5% (5) y 7,7% (1), (p = 0,85); elaboración apropiada en el 17,7%, 13,5% y 7,7%, (p = 0,61); distribución adecuada en el 8,1%, 8,1% y 0% (0), (p = 0,56). Conclusión. En los barrios de la ciudad de Buenos Aires evaluados, uno de cada cuatro locales de comida elaborada no tenía disponibilidad de al menos un plato libre de gluten. Asimismo, se detectó una importante falta de cumplimiento de las medidas de seguridad para evitar la contaminación cruzada

Analysis of the decrease in deaths due to coronary disease between 1995 and 2010. IMPACT CHD Argentina Study.

ObjetiveTo quantify the contribution of risk factors and treatments in the reduction of mortality due to coronary heart disease in Argentina between 1995 and 2010.ResultsWe used the validated IMPACTCHD model integrating data on effectiveness, use of treatments and changes in the risk factors between 1995 and 2010 in people older than 25 years in Argentina. The difference between the coronary deaths observed and expected in 2010 was distributed between treatments and risk factors.ConclusionsOne out of every two MPP due to coronary heart disease in Argentina between 1995 and 2010 was due to treatments and one third to the improvement of risk factors. The decrease in blood pressure, cholesterol and smoking was limited by increases in the prevalence of obesity, sedentary lifestyle and diabetes. This study was possible thanks to the collaborative work to the cardiovascular epidemiology

Pilares y líneas de acción para los sistemas de salud integrados y centrados en las personas y las comunidades

Se presenta el posicionamiento del grupo de trabajo latinoamericano de la Fundación Internacional para los Cuidados Integrados (1) (IFIC, por su sigla en inglés). Este reúne a diversos actores y organizaciones de América Latina, con el objeto de apoyar acciones que faciliten la transformación de los sistemas de salud en la Región hacia sistemas integrados y centrados en las personas, no como individuos aislados, sino como sujetos de derecho, en los contextos sociales y ambientales complejos donde viven y se vinculan. El grupo de trabajo plantea nueve pilares de la atención integrada para ser utilizados como marco conceptual en la elaboración de políticas y de cambios en las prácticas: 1) visión y valores compartidos, 2) salud de las poblaciones, 3) las personas y las comunidades como socias, 4) comunidades resilientes, 5) capacidades del talento humano en salud, 6) gobernanza y liderazgo, 7) soluciones digitales, 8) sistemas de pago alineados, y 9) transparencia ante la ciudadanía. Desde estos pilares se proponen líneas de trabajo en los ámbitos del fortalecimiento de alianzas y redes, la abogacía, la investigación y generación de capacidades, que contribuyan a materializar sistemas de salud y sociales efectivamente integrados y centrados no solo en las personas, sino también en las comunidades en América Latina.This paper presents the position of the Latin American working group of the International Foundation for Integrated Care (IFIC). The working group brings together various Latin American actors and organizations in support of actions that facilitate the transformation of health systems in the region towards integrated systems that focus on people not as isolated individuals but as subjects of law in the complex social and environmental contexts where they live and interact. The working group proposes nine pillars of integrated care to be used as a conceptual framework for policy development and changes in practices: 1) shared vision and values; 2) population health; 3) people and communities as partners; 4) resilient communities; 5) capacities of human resources for health; 6) governance and leadership; 7) digital solutions; 8) aligned payment systems; and 9) public transparency. Based on these pillars, lines of work are proposed to strengthen alliances and networks, advocacy, research, and capacity-building, in order to help develop health and social systems that are effectively integrated and focused not only on people but also on communities in Latin America